摘要
目的 探讨晚期非小细胞肺癌的治疗中,采用同步放化疗联合程序性细胞死亡蛋白-1(Programmed Death-1, PD-1)抑制剂帕博利珠单抗治疗的临床应用价值。方法 随机选取2022年9月—2023年10月山东省滕州市中心人民医院收治的70例晚期非小细胞肺癌患者作为研究对象,根据治疗方法的不同将其分为两组,各35例。对比组予以同步放化疗联合顺铂、吉西他滨。研究组在同步放化疗基础上联合帕博利珠单抗治疗。对两组临床效果进行评价。结果 研究组治疗总有效率(85.71%)高于对比组(62.86%),差异有统计学意义(χ^(2)=4.786,P=0.028)。两组不良反应发生情况对比,差异无统计学意义(P>0.05)。治疗后,研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于对比组,CD8^(+)低于对比组,差异有统计学意义(P均<0.05)。结论 针对晚期非小细胞肺癌,选择同步放化疗与PD-1抑制剂帕博利珠单抗联合治疗方案疗效确切,不良反应可控,具有安全性。
Objective To investigate the clinical value of concurrent chemoradiotherapy combined with programmed cell death protein-1(PD-1)inhibitor(paporizumab)in the treatment of advanced non-small cell lung cancer.Methods From September 2022 to October 2023,70 patients with advanced non-small cell lung cancer admitted to Tengzhou Central People's Hospital of Shandong Province were randomly selected as the research objects.According to the dif-ferent treatment methods,they were divided into two groups,35 cases in each group.The control group was treated with concurrent chemoradiotherapy combined with cisplatin and gemcitabine.The study group was treated with paboli-zumab on the basis of concurrent chemoradiotherapy.The clinical effects of the two groups were evaluated.Results The total effective rate of treatment in the study group(85.71%)was higher than that in the control group(62.86%),and the difference was statistically significant(χ^(2)=4.786,P=0.028).There was no significant difference in the inci-dence of adverse reactions between the two groups(P>0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the study group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group,the differences were statistically significant(all P<0.05).Conclusion The combination of concurrent chemora-diotherapy and pembrolizumab is an effective and safe treatment for advanced non-small-cell lung carcinoma.
作者
王伟
杨森
李苓
WANG Wei;YANG Sen;LI Ling(Department of OncologyⅢ,Tengzhou Central People's Hospital,Tengzhou 277599,Shandong,China;Department of OncologyⅠ,Tengzhou Central People's Hospital,Tengzhou 277599,Shandong,China)
出处
《中外医疗》
2024年第19期115-117,151,共4页
China & Foreign Medical Treatment
